CD3 Antigen Inhibitors Pipeline Research Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CD3 Antigen Inhibitors – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “CD3 antigen inhibitors – Pipeline Insight, 2021” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in CD3 antigen inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

CD3 antigen inhibitors Emerging Drugs Chapters

This segment of the CD3 antigen inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CD3 antigen inhibitors Emerging Drugs

Tebentafusp: Immunocore

Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognise and kill tumour cells. Tebentafusp has been granted Breakthrough Therapy Designation, Fast Track designation and orphan drug designation by the FDA in the United States and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. The drug is currently in phase 3 stage of development.

Cibisatamab: Roche

Cibisatamab is an intravenously administered T-cell bispecific monoclonal antibody, being developed by Roche for the treatment of Non-small cell lung cancer. Currently, it is in phase I/II stage of development.

CD3 antigen inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different CD3 antigen inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on CD3 antigen inhibitors

There are approx. 20+ key companies which are developing the CD3 antigen inhibitors. The companies which have their CD3 antigen inhibitors drug candidates in the most advanced stage, i.e. phase IIIinclude, Immunocore.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

CD3 antigen inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

CD3 antigen inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CD3 antigen inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CD3 antigen inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence CD3 antigen inhibitors R&D. The therapies under development are focused on novel approaches for CD3 antigen inhibitors.

CD3 antigen inhibitors Report Insights

• CD3 antigen inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

CD3 antigen inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Scenario and Emerging Therapies:

• How many companies are developing CD3 antigen inhibitors drugs?
• How many CD3 antigen inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for CD3 antigen inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CD3 antigen inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CD3 antigen inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Immunocore
• Roche
• Janssen Research & Development
• Celgene Corporation
• Avacta
• MacroGenics
• BioNTech
• Pfizer
• EpimAb Biotherapeutics
• Glenmark Pharmaceuticals
• Tiziana Life Sciences
• IGM Biosciences
• QLSF Biotherapeutics
• Y-mAbs Therapeutics
• Genmab
• YZY Biopharma
• Abzyme Therapeutics
• Harbour BioMed
• Aptevo Therapeutics
• IONTAS
• TeneoBio
• Cullinan Oncology

Key Products

• Tebentafusp
• Cibisatamab
• JNJ 78278343
• AVA 002
• MGD 014
• Glofitamab
• BNT142
• PF-06863135
• JNJ-64007957
• EMB-06
• EMB-07
• GBR 1302
• GBR 1342
• GBR 1372
• Foralumab
• IGM-2323
• QL315
• QL325
• Nivatrotamab
• huCD33-BsAb
• Epcoritamab
• M802
• HBM7020
• APVO436
• TNB-486
• Teclistamab
• CLN-049
• CLN-978

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/mul34b

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900